Valor predictivo de los test Enhanced Liver Fibrosis, OWLiver y Maglumi en pacientes con esteatosis hepática y alto riesgo de fibrosis avanzada.
Datos básicos
- Protocolo:
- PrediFib
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2024
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
Assessing ATR-FTIR spectroscopy for steatosis quantification in liver biopsies in a long-duration cross-sectional study
Rienda, Ivan; (...); Quintas, Guillermo
Article. 10.1016/j.microc.2024.110135. 2024
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
Lopez-Pascual, Ernesto; (...); Castell, Jose V.
Article. 10.3390/ijms25105203. 2024
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.jneuroim.2024.578428. 2024
Fibrillary glomerulonephritis: more frequent than it seems? The diagnostical importance of immunohistochemistry.
Viejo-Boyano I; (...); Hernández-Jaras J
Letter. 10.1016/j.nefroe.2023.05.022. 2024
FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis
Martinez-Arenas, Laura; (...); Berenguer, Marina
Meeting Abstract. 2024
FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH.
Martinez-Arenas, Laura; (...); Berenguer, Marina
Article. 10.1111/liv.16085. 2024
Glomerulonefritis fibrilar: ¿Más frecuente de lo que parece? La importancia de la inmunohistoquímica en el diagnóstico
Viejo-Boyano, Iris; (...); Hernandez-Jaras, Julio
Editorial Material. 10.1016/j.nefro.2023.05.001. 2024
HepatoPredict Accurately Selects Hepatocellular Carcinoma Patients for Liver Transplantation Regardless of Tumor Heterogeneity
Andrade, Rita; (...); Cardoso, Joana
Article. 10.3390/cancers17030500. 2025
IDENTIFICATION OF CANDIDATES FOR MASLD TREATMENT WITH INDETERMINATE VIBRATION- CONTROLLED TRANSIENT ELASTOGRAPHY
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2024
Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography.
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.1016/j.cgh.2024.10.014. 2024
LIPID DROPLET MORPHOLOGY JUSTIFIES DISCORDANCES BETWEEN HEPATIC STEATOSIS GRADES AND MRI PROTON DENSITY FAT FRACTION
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2024
Polyribonucleotide phosphorylase is overexpressed in hepatocellular cancer, promoting epithelial phenotype maintenance and tumor progression
Revert-Ros, Francisco; (...); Hernandez-Andreu, Jose Miguel
Article. 10.1016/j.prp.2024.155713. 2024
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2024.105734. 2024
Prognosticating hepatocellular carcinoma before and after liver transplantation with HepatoPredict
Silva, Silvia Gomes; (...); Cardoso, Joana
Meeting Abstract. 2024
Telemonitoring with TECCU of active Inflammatory Bowel Disease is Not Inferior to Standard Care: Short-term Results of a Multicentre Randomized Controlled Trial of GETECCU.
Article. 10.2196/60966. 2024
The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis
Soluyanova, Polina; (...); Jover, Ramiro
Article. 10.3390/biom14111423. 2024